Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Same disease, wildly different outcomes — and now we know why. Researchers studying a nine-generation family with facioscapulohumeral muscular dystrophy (FSHD) found that DNA methylation acts like a dimmer switch on the disease-causing DUX4 gene, dialing down its activity and leading to milder symptoms. The discovery could reshape how doctors predict disease progression and develop new treatments.
Two siblings. Same rare genetic disease. Completely different lives. One brother could barely walk by his 50s; his sister remained nearly symptom-free into her late 30s. That striking contrast has puzzled scientists for years — and a new study published in Brain may finally explain it.
Researchers at the University of Utah studied a nine-generation family with facioscapulohumeral muscular dystrophy (FSHD), a condition caused by abnormal activation of the DUX4 gene in adulthood. Using a custom long-read sequencing tool, they found that higher levels of DNA methylation at DUX4 — essentially a molecular "dimmer switch" — were strongly associated with milder disease symptoms. They also identified a second gene, HDGFL3, that appears to influence how much methylation occurs at DUX4, making it a potential new therapeutic target.
Key Takeaways:
Why it matters: For patients living with FSHD, this discovery opens the door to better prognostic tools and targeted therapies that could slow or even prevent severe disease progression.